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Exposure to ultraviolet radiation can modulate
immune responses in animal and humans.
Remarkably, the ultraviolet-induced immunosup-
pression is not restricted to the exposed skin but is
also found at other body sites, i.e., systemic immuno-
suppression. Effects of ultraviolet radiation on infec-
tions cannot be determined by experimentation on
humans, but the effects of ultraviolet on vaccination
may serve as a model. Moreover, it is important in its
own right to assess whether ultraviolet radiation
affects vaccination responses. In this study the effect
of ultraviolet B exposure on the development of
immune responses after hepatitis B vaccination in
human volunteers was investigated. To this end, 191
human volunteers were vaccinated against hepatitis B
with the Engerix-Bâ vaccine. Ninety-seven of them
were prior to the ®rst vaccination exposed to ultra-
violet B on 5 consecutive days with one personal
minimal erythema dose per day. At several time-
points before and after the ultraviolet B exposure
regimen and the vaccination, blood samples were
taken. Parameters for speci®c as well as nonspeci®c
cellular and humoral immunity were analyzed. It was
demonstrated that ultraviolet B exposure prior to
hepatitis B vaccination did not alter the cellular (lym-
phocyte stimulation test) nor the humoral (antibody
titers) immune response against hepatitis B surface
antigen signi®cantly. In contrast, contact hypersensi-
tivity to diphenylcyclopropenone was signi®cantly
suppressed after ultraviolet B exposure, as was natural
killer cell activity. These latter results con®rm earlier
®ndings and demonstrate immunosuppressive effect-
iveness of the ultraviolet regimen. In summary,
although natural killer cell activity and contact hyper-
sensitivity responses were suppressed, the ultraviolet
B radiation protocol did not alter the humoral nor
the cellular immune responses against hepatitis B
surface antigen after vaccination. Key words: hepatitis B
vaccination/human volunteers/ultraviolet immunomodula-
tion. J Invest Dermatol 117:1144±1150, 2001
O
ver the last two decades it has become clear that
ultraviolet (UV) B exposure (280±315 nm) in¯u-
ences speci®c and nonspeci®c immune responses
(Hurks et al, 1994). This immunomodulation is
likely to exert therapeutic effects on some skin
diseases (e.g., psoriasis) and might impair some allergic and certain
autoimmune diseases such as multiple sclerosis (McMichael and
Hall, 1997; Abel, 1999; Garssen et al, 1999); however, UV-induced
immunosuppression could also have deleterious effects on human
health. The best known nonimmunologic deleterious effects are
sunburn and ocular damage (snow blindness, cataract). Using
animal models, UV-induced immunosuppression has been shown
to play an important part in photocarcinogenesis (Kripke, 1981;
Nishigori et al, 1996). In addition, UV exposure has been
demonstrated to impair resistance to bacterial, viral, parasitic, and
fungal infections. Importantly, the effects of UV radiation are not
restricted to skin-associated infections, but are also found in
systemic (nonskin-associated) infections (Garssen et al, 1998).
Owing to the fact that UVB is not able to penetrate much beyond
the epidermis, UVB-induced immunosuppression is likely to be
mediated by cells or their products or photo-activated factors
present in the skin.
It has been demonstrated that the UV-induced factors modulate,
in particular, natural killer cells, antigen-presenting cells, and T
helper cells. Based on their cytokine pro®les T helper cells can be
subdivided into at least two subsets, T helper 1 (Th1) and T helper
2 (Th2). Th1 cells release, in particular, interleukin-2 and
interferon-g, whereas Th2 cells mainly release interleukin-4, -5,
-6, and -10. The majority of studies dealing with UV-induced
immunomodulation that have been performed so far indicated that
Th1-mediated immune responses, i.e., cellular responses, are
especially sensitive to UV exposure (Araneo et al, 1989; Simon
et al, 1994). Recent studies, however, indicate that UV exposure
not only impairs Th1 responses but also some Th2-responses
(Goettsch et al, 1994; Garssen et al, 1999; Van Loveren et al 2000;
Brown et al, 2001; Ward et al, 2001).
It has been suggested that the response to vaccination might be a
useful indicator of effects on the immune system induced by
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exposure to environmental agents (Van Loveren et al, 1999, 2001).
Therefore, in this study vaccination responses in human volunteers,
in this case hepatitis B vaccination, was chosen as a model to
investigate the immunomodulating effects of UV light in humans.
The hepatitis B virus (HBV), has a worldwide distribution,
having infected more than 2 billion people of the current
population and more than 350 million people are chronic carrier
of the virus. This amounts to more than 5% of the entire population
of the world (Lee, 1997). Following acute hepatitis B infection, 5±
10% of the adult patients develop persistent infection that may lead
to chronic hepatitis, cirrhosis, and hepatocellular carcinoma,
accounting for 1 million deaths annually. Recombinant hepatitis
B surface antigen (HBsAg) provides the basis for the HBV vaccines
currently available. The licensed yeast-derived vaccine is composed
of a nonglycosylated recombinant protein of 226 amino acids
corresponding to the complete S-type HBsAg sequence (McAleer
et al, 1984). The success of HBV immunization programs attests to
the role of neutralizing antibodies against the common ``a'',
determinant, but in addition to humoral immune responses also
cellular immune responses are surely involved in protection (Jung
et al, 1994). Evidence supports the role of the cellular rather than
the humoral immune response in the pathogenesis of HBV-
associated liver disease (Mahoney, 1999). Several vaccination
programs have been started all over the world to prevent the
transmission of HBV. As it is known that UV exposure of the skin
can mediate suppression of especially cellular but also humoral
immunity, it is postulated that such a suppression might affect
hepatitis B vaccination.
Besides providing useful information on vaccination ef®cacy,
UV-induced modulation of responses to hepatitis B vaccination
will provide a good research model to study whether UV radiation
can alter resistance to infections in humans in general. Research
dealing with such health effects of UV is necessary as humans are
exposed to increased amounts of solar and/or arti®cial UV.
``Increased'' because of a decreased ozone layer and because of a
changed lifestyle such as sunny holidays and use of arti®cial
sunlamps. After vaccination against hepatitis B, cellular and
humoral responses can be measured easily and thereby potentially
altered responses due to UVB-induced immunomodulation can be
assessed.
The present human prospective cohort study is designed to
investigate the effect of repeated arti®cial UVB exposure on
hepatitis B vaccination in human volunteers under controlled
conditions.
MATERIALS AND METHODS
Volunteers Healthy volunteers, aged between 19 and 52 y, were
recruited from the local university (students and staff) and hospital staff.
This study was performed during winter to avoid outdoor sunlight
being a major in¯uence. Exclusion criteria included history of suntanning
within the prior month to vaccination, and prior vaccination against
hepatitis B. Subjects were not allowed to sunbathe during the entire
study. After inclusion the subjects were randomized to receive the UVB
exposure or to act as unexposed controls. Each volunteer was fully
informed about the procedures and gave written informed consent before
entering the study, which was approved by the medical ethical commit-
tee of the University Medical Center Utrecht.
The volunteers were included randomly in two consecutive winters
(years 1998±99 and 1999±2000) in two different cohorts in six different
groups per cohort. The total number of volunteers that were included
was 191 (61 males and 130 females). Ninety-seven were irradiated with
UVB and 94 acted as controls. The median age of the volunteers was
21 y (range 19±52 y). Three volunteers were excluded from the study
because of the presence of anti-HBs antibodies at the ®rst time-point and
one of them was anti-HBc positive. One volunteer did not complete the
study.
Time-course of the protocol T = ±11, day of testing minimal
erythema dose (MEDjp), lymphocyte stimulation test (LST), natural killer
cell activity and anti-HBs analysis; T = ±7 to T = ±3, days of UV
radiation; T = 0 d of ®rst vaccination, sensitization to diphenylcyclo-
propenone (DCP), LST, natural killer cell activity, and anti-HBs
determination; T = 14, day of primary allergic reaction (PAR) analysis,
LST, and anti-HBs determination; T = 32, day of second vaccination,
challenge with DCP and anti-HBs analysis; T = 35, day of anti-HBs
analysis; T = 38, day of LST and anti-HBs determination; T = 46, day
of anti-HBs determination; T = 60, day of anti-HBs determination.
UV radiation source and dosimetry UV irradiation was carried out
in an upright cabinet equipped with 16 Philips TL12 100 W ¯uorescent
lamps (Philips, Eindhoven, the Netherlands) emitting broadband UVB
(280±315 nm). Irradiance was measured with a calibrated Waldmann
UVB meter (Waldmann GmbH, Villingen-Schwenningen, Germany)
and the average intensity was 0.80 mW per cm2 UV (280±400 nm).
Determination of the MEDjp The MEDjp was de®ned as the UVB
dose that induces a just perceptible erythema at 24 h after exposure. The
MEDjp was determined for each individual volunteer. This assessment
was carried out 4 d before the experiment started (T = ± 11) on back
skin with a panel of Philips TL12 lamps [57.5% of UV output in UVB
(280±315 nm)] by a geometric exposure series of nine sites using a Ö2
incremental dose series. MEDjp ranged from 186.3 to 1040.0 J per m
2
UVB (see Table I).
Exposure protocol Volunteers received total body UVB exposure on
5 consecutive days (T = ±7 to T = ±3). Initial exposure started with one
predetermined personal MEDjp that induced only a very faint erythema
to limited areas or no discernable erythema at all. Each successive
exposure dose was increased by 10%, with the following exceptions: if
the previous exposure had caused mild erythema, the dose was not
increased and if it had caused no erythema at all, the dose was increased
by 20% (see Table I).
Contact hypersensitivity (CHS) protocol Volunteers who were
already included in the study were asked whether they were willing to
participate in an additional study in which CHS responses were assayed
to determine the immunosuppressive effectiveness of the UVB
exposures. Twenty-®ve volunteers of the second cohort agreed to
participate, 13 volunteers were exposed to UVB prior to sensitization
and 12 volunteers acted as controls. Two volunteers did not want to
continue after the sensitization. One volunteer was advised to stop as this
volunteer showed signs of a systemic reaction (acute eczematous lesions
on the palms and ®ngers) within 2 wk after the sensitization. Volunteers
were sensitized on irradiated skin of the upper arm with DCP 3 d after
irradiation, together with the ®rst vaccination against hepatitis B (T = 0).
Sensitization to DCP was performed on the irradiated skin of the UVB-
exposed individuals by applying two 7 mm paper ®lter disks (Epitest Ltd
Oy, Tuusula, Finland), soaked in 20 ml of 0.1% DCP in acetone (40 mg
per 40 ml) to the skin; controls received the sensitization at the same, but
unirradiated site. The paper ®lter disks were mounted inside 8-mm
aluminum Finn chambers (Epitest Ltd Oy) and taped in place for 48 h.
Two weeks after the sensitization (T = 14) the PAR was determined.
Table I. Minimal erythema doses (MEDjp) and total amount of received UVB dose (5 consecutive days, 1 MEDjp per day)
of included volunteers
MEDjp (J per m
2) Dose (J per m2)
n Mean SD Median Min. Max. Mean SD Median Min Max.
1st cohort 50 432.7 136.0 416.9 250.0 728.0 2263.8 595.8 2108.8 1456.0 3886.8
2nd cohort 47 447.8 157.0 430.5 186.3 1040.0 2421.1 624.4 2352.8 1309.0 4095.0
Totala 97 440.0 146.0 424.2 186.3 1040.0 2340.0 611.7 2222.0 1309.0 4095.0
aTwo cohorts combined.
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Four weeks after the sensitization (T = 32), volunteers received an
antigen challenge on the unirradiated lower inner arm, which was
covered during UV treatment of UV-exposed individuals. Paper ®lter
disks (7 mm) were placed in 8 mm Finn chambers and soaked with
20 ml of antigen solutions of various strengths: 0.002%, 0.004%, 0.008%,
0.016%, and 0.032% DCP. The UV-exposed individuals were patched
with all concentrations, except when they had developed a PAR, then
the highest concentration was excluded. The control volunteers were
challenged with the two lowest concentrations only to minimize the
discomfort. As a control, an acetone patch was used. These patches
remained in place for 6 h, and at 48 h and 96 h the sites were evaluated.
The visual evaluation of the responses was recorded using the criteria of
the International Contact Dermatitis Research Group (IDCRG): (0) ±,
no reaction; (1) +?, macular erythema; (2) +, erythema with in®ltration;
(3) ++, erythema with in®ltration and papules or vesicles; and (4) +++,
bullous reaction (Rietschel and Fowler, 1995). Quantitative
measurements of erythema were made in triplicate using a Minolta
chromameter CR-200 (Minolta Camera Co., Ltd, Higashi-Ku, Japan).
For each individual, the increase in erythema was calculated by
subtracting the mean background of adjacent nonirradiated skin.
Photographs were also obtained.
Vaccination Volunteers were vaccinated against hepatitis B by
intramuscular (i.m.) administration in the upper arm with a vaccine
containing a 20 mg dose of recombinant HBsAg (Engerix-B;
Glaxosmithkline Biologicals (GSK), Belgium) according to a 0, 1, and
6 mo vaccination schedule. The vaccines contained aluminum hydroxide
as an adjuvant and were preserved with thiomersal. The ®rst vaccination
was given 3 d after the UV exposure (T = 0). The third vaccination was
provided to complete the vaccination regimen. As it was not possible to
demand from the study participants to restrain from sun exposure for an
additional 5 mo, especially in summertime, we have not included
vaccination titers after the third vaccination in our study. If volunteers
had serum anti-HBs antibodies before entry into this study, they were
excluded.
Blood sampling At several time-points during the protocol, blood
was drawn with a 10 ml Vacutainer tube (Becton Dickinson, Meylan,
France) from the volunteers. Eight serum samples were obtained from
each volunteer: before vaccination (T = ±11 and T = 0: before and after
UVB exposure, respectively), 2 wk after the ®rst vaccination (T = 14),
before the second vaccination (T = 32), 3 d, 6 d, 2 wk, and 1 mo after
the second vaccination (T = 35, T = 38, T = 46, and T = 60,
respectively).
Lymphocyte isolation At four time-points, T = ±11, T = 0, T = 14,
and T = 38, approximately 50 ml blood was collected from each
volunteer in Vacutainer CPT tubes containing sodium heparin and
Ficoll-Isopaque (Becton Dickinson, Franklin Lakes, NJ). Peripheral
blood mononuclear cells (PBMC) were obtained by gradient
centrifugation. Subsequently, PBMC were washed twice with PBS and
counted with the Coulter Counter (Coulter Electronics Limited, Luton,
Beds, U.K.), after which they were brought to concentration with
RPMI 1640 medium supplemented with 10% inactivated human
AB + serum (anti-HBs negative), 100 IU penicillin per ml and 100 mg
streptomycin per ml.
Lymphocyte stimulation test Human PBMC, freshly isolated from
blood on the same day of blood sampling, were cultured at 1 3 105 cells
per well (or 4 3 105 cells per well in the case of HBsAg) in a 96 well
round-bottom plate (Greiner Bio-one B.V., Alphen a/d Rijn, the
Netherlands) in triplicate for each mitogen or antigen at 37°C and 5%
CO2. Pokeweed mitogen (Gibco Liftechnologies BV, Breda, the
Netherlands) or phytohemagglutinin (PHA; Murex Biotech, Dartford,
U.K.) were added at ®nal concentrations of 75 mg per ml, 37.5 mg per
ml or 18.75 mg per ml for PHA and 1:240, 1:480, or 1:960 diluted for
pokeweed mitogen (PWM). For recall antigens Diphtheria and tetanus
toxin (SVM, Bilthoven, the Netherlands) were added together at a
concentration of 3.3 limits of ¯uctuation (Lf) per ml. For antigen-speci®c
stimulation HBsAg (GSK) was used at 1, 3, and 5 mg per ml ®nal
concentration. After 5 d incubation at 37°C and 5% CO2, 10 ml (1 mCi)
of [3H]thymidine (Amersham Pharmacia Biotech., Buckinghamshire,
U.K.) was added to each well and incubated for an additional 20±22 h.
Cells were then harvested on glass-®ber ®lters (LKB-Wallac, Turku,
Finland) using a multiple cell culture harvester (LKB-Wallac).
Scintillation liquid (LKB-Wallac) was added to the ®lters and the activity
was counted in a liquid scintillation counter (LKB-Wallac). Each test was
performed in triplicate. For calculation of the results from each subject,
the highest and lowest values were not used. Antigen speci®c cell
proliferation was presented as the subtractions: this was de®ned as the
counts per minute (cpm) of [3H]thymidine incorporation in the presence
of a stimulus minus the cpm of [3H]thymidine incorporation in the
absence of a stimulus.
Natural killer cell assay
Labeling target cells for natural killer cell assay K562 lymphoma cells
(1 3 107 cells per ml), were labeled with 3.7 MBq 51Cr per 106 cells.
After incubation for 45 min at 37°C, cells were washed ®ve consecutive
times with complete medium (RPMI 1640 medium supplemented with
10% inactivated fetal bovine serum, 100 IU penicillin per ml and 100 mg
streptomycin per ml) and resuspended at a concentration of 5 3 104
viable K562 cells per ml.
Removal of adherent cells Isolated PBMC were incubated at 2 3 107 cells
per ml, 1 ml per well, in a 12 well Costar culture plate overnight at
37°C and 5% CO2. After incubation, the nonadherent cells were
removed and counted with the Coulter Counter. Finally, the cells were
brought to concentrations of 1.25 3 106, 2.5 3 106, 5 3 106, and
1 3 107 cells per ml.
Assay Cell suspensions (0.1 ml) of each concentration were plated in
triplicate in polystyrene 96 well Costar plates. Labeled K562 (0.1 ml) was
added. The plates were centrifuged at 300 3 g for 5 min and incubated
for 4 h (37°C and 5% CO2). After incubation, the plates were
centrifuged again at 300 3 g for 5 min. The supernatant was extracted
using a harvesting frame with cartridges (Skatron Instruments, Lier,
Norway) and a harvesting press (Skatron). The cartridges were pushed
down into the wells with the press. The press was pushed back and the
cartridges (without ®lter discs) were inserted on to the bottom of
Macrolowell tubes (Skatron) and these tubes were put into vials
(Packard, BioScience Benelux, Zellik, Belgium). The vials were counted
with a g-counter (Ninaxi autogamma 5650, Packard, UK). Spontaneous
release (S) was about 11.2% of maximum. The maximum release (M)
was determined by incubating labeled cells with 0.1 ml 1% Triton X100
(Merck, Darmstadt, Germany). The percentage speci®c release (SP) is
calculated according to the formula (E = experimental release):
SP = ((E ± S)/(M ± S)) 3 100. The speci®c release (SP) was about 55%,
45%, 32%, or 20% depending on the target-to-effector cell ratio, 1:200,
1:100, 1:50, or 1:25, respectively. The viability of cells in suspension was
determined by trypan blue exclusion (0.5% in PBS).
Anti-hepatitis B antibody determination
Total anti-HBs antibody determination The quantitative determination of
antibody titers to anti-HBsAg (anti-HBs) was performed by
Microparticle Enzyme Immunoassay (MEIA) using Axsym (Abbott
Laboratories, Chicago, IL). Brie¯y, serum was added to recombinant
HBsAg, subtypes ad and ay) coated microparticles. When anti-HBs is
present in the serum, it binds to the coated microparticles. This mixture
was transferred to a matrix cell, where microparticles were bound
irreversibly to a glass ®ber matrix. Biotinylated recombinant HBsAg was
dispensed on to the matrix cell. Subsequently, anti-biotin±alkaline
phosphatase was added. After washing, 4-methylumbelliferyl phosphate
was added as a substrate. The alkaline phosphatase-labeled conjugate
catalyzes the removal of a phosphate group from the substrate, yielding
the ¯uorescent product, 4-methyllumbelliferone, which was measured by
the MEIA optical assembly. The concentration of anti-HBs in the sample
was determined using a previously generated calibration curve. The
calibration curve was determined with samples that contain different
concentrations of anti-HBs standardized against the World Health
Organization Reference Standard.
Anti-HBs isotype determination Assays were performed on ¯at bottom 96
well plates (NUNC-Immuno Plate, Roskilde, Denmark). Plates were
washed four times with a 0.05% solution of Tween-20 (Fluka,
Zwijndrecht, the Netherlands) in PBS between all steps (200 ml per
well). The plates were coated with 2.5 mg per ml HBsAg (GSK) (50 ml
per well) in bicarbonate buffer (0.1 M, pH 9.5) and incubated overnight
at room temperature. The following day, after washing, serum was added
to the wells (1:10 diluted for IgG1 determination and 1:4 diluted for
IgG2, IgG3, and IgE determination in PBS-Tween 0.05%, 100 ml per
well). As a standard, pooled human serum with detectable anti-HBs
antibodies was used. This was added to the wells in a serial dilution in
PBS-Tween 0.05%. After a 1 h incubation (room temperature), the
plates were washed and the appropriate secondary antibody was added
(100 ml of a 1:1000 dilution) of a biotinylated mouse anti-human IgG1,
IgG2, IgG3, or IgE (Pharmingen, San Diego, CA) for 1 h (room
temperature). After washing, 100 ml (1:50,000 dilution) poly-horseradish
peroxidase conjugated streptavidin (Strepta-E+, Central Laboratory of the
Blood Transfusion Service, Amsterdam, the Netherlands) was added to
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each well for 1 h. After washing, 150 ml orthophenylenediamine
substrate was added to each well and allowed to develop for 30 min All
the plates were read for absorbance at 492 nm.
Anti-herpes simplex virus (HSV) IgG and IgM determination
Antibody titers against HSV-1 were determined with a commercially
available enzyme-linked immunosorbent assay kit (Virotech, Genzyme
Virotech GmbH, Ruesselsheim, Germany) according to the manu-
facturer's instruction. Brie¯y, sera of human volunteers were diluted
1:100 with dilution buffer and than added to coated microtiter strips
with HSV-1 in duplicate. After 30 min incubation at 37°C, plates were
washed four times with washing solution. Subsequently, peroxidase-
conjugated anti-human IgG or IgM was added to the plate and
incubated for 30 min at 37°C. After extensively washing, tetramethyl-
benzidine was added as a substrate and incubated for 30 min at 37°C.
The reaction was stopped with citrate solution and read at 450 nm to
measure extinction (OD). Within each test IgG-, IgM-positive, negative,
and cut-off controls were added as well as dilution buffer as blank
control. The OD values of the blank were subtracted from all
extinctions. The HSV-1 titers of the tested sera were expressed as
Virotech units (VE). These VE were calculated as follows: VE
(serum) = (OD patient serum/OD cut-off control) 3 10. VE higher
than 11.0 were considered as positive, between 9.0 and 11.0 equivocal
and lower than 9.0 negative.
Statistical analysis Levels of statistical differences were calculated with
the Statistical Package SPSS 10.0. Kolmogorov±Smirnov was used in
order to determine the distribution of the values (i.e., normal
distribution or binomial, etc.). Levene's test was used for determining the
homogeneity of variance. For paired tests, paired samples T-tests (in
normal distribution and equality of variances) or Wilcoxon signed rank
tests (in nonparametric distribution) were used (two-sided). For
nonpaired tests, independent samples T-tests (in normal distribution and
equality of variances) or Mann±Whitney U tests (in nonparametric
distribution) were used (two-sided). ANOVA was used in the case of
multiple comparisons. If signi®cance was shown using the ANOVA,
differences between groups were tested using the multiple comparison
F-test. For correlations the Spearman correlation coef®cient was used.
RESULTS
Immunosuppressive effects of the used UVB exposure
regimen
A daily dose of 1 MED UVB for 5 consecutive days induced a suppression
of natural killer cell activity in human volunteers To check whether
the UVB exposure regimen induced systemic effects on the
immune system, the effects on natural killer cell activity were
tested. When all the target±effector cell ratios were taken into
account, there was a signi®cant difference in natural killer cell
activity after UVB exposure (T0), between the UVB-exposed and
nonexposed individuals (ANOVA p < 0.01) (data not shown). The
UVB-exposed individuals showed a signi®cant suppression after
the irradiation protocol. This indicated that irradiation on 5
consecutive days with 1 MEDjp per day total body, induced a
systemic effect on the innate, nonspeci®c immune system.
Contact hypersensitivity responses were suppressed after UVB
exposure To establish the immunosuppressive effectiveness of
our UVB exposure regimen further an earlier performed
sensitization protocol with DCP was used (Koulu et al personal
communication). Eleven (84.6%) of 13 UV-exposed volunteers
and all nonirradiated controls (100%) developed a PAR. This
showed that DCP was a very strong sensitizer. Twenty-two of the
25 volunteers were challenged with incremental doses of DCP.
UVB-exposed individuals showed a signi®cant suppressed
elicitation response compared with controls, assessed by visual
scoring and quantitative measurement by re¯ectivity using a
chromameter (Minoltameter) of the skin reactions (data not
shown). Photographs of typical elicitation responses are presented
in Fig 1. UVB-exposed individuals showed suppressed elicitation
responses, i.e., no response at all concentrations (Fig 1a) or only
responses at high concentrations of DCP (Fig 1b). Unexposed
controls showed elicitation responses at all concentrations of DCP
(Fig 1c). Hence, the UV exposure regimen was suf®cient to
suppress CHS responses to DCP.
HSV-positive individuals did not show differences in HSV-speci®c IgG or
IgM titers after exposure to UVB Besides the in¯uence of UVB
radiation on immune responses after vaccination, the in¯uence on an
already established herpes simplex infection was tested. All UVB-
exposed individuals (99) were tested for anti-HSV-1 antibodies (IgG
and IgM); 43 were positive (43.4%) and 56 were negative (56.6%).
The positive individuals were tested for antibody titers at several
time-points during the protocol and showed no difference in anti-
HSV IgG nor anti-HSV IgM with time (data not shown).
Effects of UVB exposure on vaccination responses
Lymphocyte responses to PHA and PWM were signi®cantly increased after
vaccination against hepatitis B Lymphocyte proliferation tests were
performed at different time-points with two different mitogens,
PHA (Fig 2a) and PWM (Fig 2b). Both responses were
signi®cantly increased after vaccination against hepatitis B, already
2 wk after the ®rst vaccination and this further augmented after the
second vaccination (p < 0.001). UVB exposure prior to vaccination
did not affect these mitogen responses.
UVB radiation further augmented an increment in lymphocyte responses to
the recall antigens Diphtheria and tetanus toxoid after hepatitis B
vaccination In addition to mitogenic responses of lymphocytes the
modulation by UV of responses to recall antigens were tested. We
tested Diphtheria and tetanus as nearly all adults were vaccinated
against these agents. After vaccination against hepatitis B, an
increased response to these recall antigens was found, as depicted in
Fig 2c. UVB exposure seemed to induce the increment earlier after
vaccination, i.e., 2 wk after the ®rst vaccination.
UVB irradiation prior to vaccination against hepatitis B did not affect
in vitro antigen-speci®c lymphocyte proliferation to HBsAg The
Figure 1. Photographs of elicitation respon-
ses after sensitization and challenge with
DCP. Volunteers exposed to UVB for 5
consecutive days show a marked suppression after
challenge with DCP (a,b), compared with control
volunteers (c). C = acetone control; 2 = 0.002%
DCP; 4 = 0.004% DCP; 8 = 0.008% DCP;
16 = 0.016% DCP; 32 = 0.032% DCP.
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antigen-speci®c cellular response to HBsAg, as measured by LST,
was already increased 2 wk after the ®rst vaccination, with a further
increment after the second vaccination (Fig 2d). Overall, UVB
exposure did not signi®cantly alter this response when UV-exposed
individuals were compared with controls, but there was a tendency
to an increment after UVB exposure. The increase in response
2 wk after the ®rst vaccination was only signi®cant for UVB-
exposed individuals when compared with the previous time-point
(T = 0), but not for nonexposed controls.
Antibody titers against HBsAg after hepatitis B vaccination were not altered
by UVB irradiation As can be seen in Fig 3, there was no
signi®cant difference in antibody titers between UVB-exposed and
nonexposed individuals, but there again seemed to be a tendency to
an increment after UVB exposure. In addition, analysis of anti-HBs
IgG1, IgG2, IgG3, and IgE indicated that UVB did not affect
antibody subclasses (data not shown).
The magnitude of humoral responses correlates with the
magnitude of the cellular responses (p < 0.05). In other words,
individuals with high antibody titers also showed high LST
responses to HBsAg.
DISCUSSION
In this study it was demonstrated that UVB exposure prior to
hepatitis B vaccination did not alter the cellular (LST) nor the
humoral (antibody titers, total and isotypes IgG1, IgG2, IgG3, or
IgE) immune response against HBsAg signi®cantly. The total dose
of UVB radiation that the volunteers received in 5 d was proven to
be immunosuppressive, as the natural killer cell activity (nonspeci®c
immunity), and CHS responses (speci®c immunity), were signi®c-
antly suppressed.
UV-induced suppression of natural killer cell activity has been
observed in studies with human volunteers (Hersey et al, 1983).
Therefore, natural killer cell activity was tested to determine the
immunosuppressive effects of the present UVB exposure regimen.
Indeed, a slight, but signi®cant, suppression of natural killer cell
activity after irradiation with broadband UVB (TL12) was found.
Herewith, data from Neill et al (1998) were con®rmed. In contrast,
Gilmour et al (1993a,b) showed in psoriasis patients a signi®cant
suppression of natural killer cell activity after psoralen + UVA or
narrowband UVB (TL01) treatment but not after broadband UVB
(UV6). In addition to this, Guckian et al (1995) performed a similar
Figure 2. Lymphocyte responsiveness. Lymphocyte proliferation responses to PHA (a), PWM (b), recall antigens (Diphtheria and tetanus toxoid) (c)
and HBsAg (d) at four time-points (T = ± 11, T = 0, T = 14 and T = 38). Cell proliferation is presented as counts per minute of [3H]thymidine
incorporation in the presence of a stimulus minus the counts in the absence of a stimulus (mean6SEM) (vertical axis). #p < 0.05; ##p < 0.01;
###p < 0.001 compared with previous time-point in the same group. Lymphocytes were cultured at 1 3 105 (PHA, PWM, and recall-antigens) or
4 3 105 cells per well in a 96-well round-bottom plate in triplicate with PHA, PWM, recall antigens, or HBsAg in three different concentrations.
Pictures present proliferation responses of PHA 18.75 mg per ml, PWM 1:960 diluted, Diphtheria/tetanus toxoid 3.3 Lf per ml and HBsAg 5 mg per ml
®nal concentration. After 5 d, 10 ml of [3H]thymidine was added to each well and incubated for an additional 20±22 h, at 37°C and 5% CO2 after
which cells were harvested.
Figure 3. Serology: HBsAg-speci®c antibody titers after hepatitis
B vaccination of control and UVB-exposed volunteers. The
horizontal axis shows the different time-points during the protocol:
T = ± 11 before UVB exposure; T = 0 after UVB exposure and the ®rst
vaccination; T = 32 second vaccination. The antibody titers are
expressed as international units per l (mean6sem). = UVB exposure;
¯ = hepatitis B vaccination; #p < 0.05; ##p < 0.01; ###p < 0.001
compared with previous time-point in the same group. UVB exposure
does not affect the development of antibody response after hepatitis B
vaccination. No signi®cant difference between the UVB-exposed and
control volunteers in antibody titers, but a tendency to increment after
UVB exposure.
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study in which a suppression of natural killer cell activity was only
found after narrowband UVB therapy. Thus, differences in natural
killer cell modulation might be due to UV doses as well as UV
wavebands the volunteers are exposed to.
Besides suppression of natural killer cell activity by the present
UVB exposure regimen, a signi®cant suppression of CHS response
was found. Contact allergens have been extensively used to
determine UV modulating effects on the sensitization and challenge
or effector phase of CHS responses in humans (Yoshikawa et al,
1990; Kelly et al, 1998). Our study shows a UVB-induced
suppression of the elicitation response after sensitization with DCP
on irradiated skin, which is in line with literature (Koulu et al
personal communication; Cooper et al, 1992; Friedli et al, 1993;
Skov et al, 1997). This shows that the used UVB exposure regimen
in our study can induce suppression of cellular immune responses.
Notwithstanding these immunosuppressive effects, a signi®cant
modulating effect of UVB on immunity induced by hepatitis B
vaccination was not found. Several reasons for this lack of
detectable immunomodulation induced by UV are described
below.
One reason may have been that, the hepatitis B vaccine that was
used in this study contains aluminum hydroxide (Al(OH)3) as an
adjuvant. Previous studies show that Al(OH)3 directs the immune
response towards a Th2 response, which is particularly responsible
for the induction of antibody responses (Gupta, 1998). As UVB
exposure suppresses particularly the Th1 responses by favoring a
Th2 environment, a promoting effect of UVB to the already Th2-
skewed vaccination response may occur. For this reason, a vaccine
that induces, in particular, Th1-skewed immunity will be interest-
ing to analyze. Unfortunately, most vaccines, including vaccines
Diphtheria and tetanus are no alternative, as these vaccines also
contain Al(OH)3. Although UV can affect both Th1 and Th2
depending immunity, there is a consensus in the literature that, in
particular, Th1 dominated responses are sensitive for UV. A
changed Th1±Th2 balance is in line with the observations that UV
radiation aggravates systemic lupus erythematosus, which is con-
sidered to be a Th2-dependent disease (Vila et al, 1999). Another
observation to support this, is the positive correlation of latitude,
which might be explained by UV exposure, with multiple sclerosis,
a more Th1-dependent disease (McMichael and Hall, 1997);
however, it should be realized that in mice, UV exposure can
suppress both Th1 and Th2 responses (Goettsch et al, 1994; Garssen
et al, 1999; Van Loveren et al, 2000; Brown et al, 2001; Ward et al,
2001).
A second reason may have been the dose of the vaccine that may
have played a part. Engerix-Bâ vaccine was used according to the
manufacturer's instructions (GSK): three vaccinations intramuscu-
larly, 20 mg per vaccination. It is known from the literature that
individuals react differently to the hepatitis B vaccines, and that not
all individuals will develop suf®cient amounts of antibodies.
Whether a person responds well or poorly to the vaccines, is
correlated with the type of HLA-DR (Caillat-Zucman et al, 1998;
Desombere et al, 1998). The dose of antigen in the vaccines is
therefore chosen in such a way that immune responses in poor
responders are also induced. From UV-modulating studies with
contact allergens, it is known that the level of immunosuppression
depends on the dose of the allergen, and that there was less
suppression of CHS when high doses of sensitizer were used
(Miyauchi and Horio, 1995). So, a possible explanation for the fact
that no UVB-induced immunosuppression was found, is the high
dose of the vaccine. Hence, at the vaccination doses used, an effect
of UV might be undetectable.
In summary, signi®cant effects of UVB exposure on standard
vaccination to hepatitis B were not found in human volunteers
under the present conditions. It should be realized, however, that
an effect of UV radiation might become evident under different
circumstances, e.g., lower doses of vaccine, other vaccination
routes (e.g., via the skin), or with other adjuvants (more Th1
skewing). Furthermore, experiments in different strains of mice
emphasize that individual differences in susceptibility to UV-
induced immunosuppression should also be considered. Hence
further research is necessary to understand fully the mechanisms of
UV-induced modulation of immunity in the context of infections
and vaccinations.
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